Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
Huan Yu, Vincent C Woo Department of Medicine, Division of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada Aims: The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination in the m...
Guardado en:
Autores principales: | Yu H, Woo VC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dbb34e9ada984dba808d4585df353ff7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016) -
Saxagliptin for type 2 diabetes
por: Chacra
Publicado: (2010) -
New prospects in the treatment of diabetes mellitus
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012) -
Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki S, et al.
Publicado: (2020) -
A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
por: Shen L, et al.
Publicado: (2021)